Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme
Executive Summary
FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.
You may also be interested in...
FTC Objections To Pharma Mergers Could Go Unchallenged Following Wilson’s Resignation
The commission no longer has a voice opposing aggressive antitrust enforcement actions and President Biden's replacement may be more receptive to the stance of the three current Democratic commissioners. Amgen’s proposed acquisition of Horizon is facing FTC scrutiny.
Prior Bad Conduct By Pharma Companies Could Be ‘Plus Factor’ In Merger Review
Experts suggest US FTC and DOJ retrospectively assess whether a merger gives companies increased leverage with PBMs and consider how it will impact vulnerable communities. Rutger’s Michael Carrier says there should be a presumption against mergers between two large firms.
Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise
Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.